Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C5H12N2O2.C4H7NO4 |
| Molecular Weight | 265.2637 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCC[C@H](N)C(O)=O.N[C@@H](CC(O)=O)C(O)=O
InChI
InChIKey=IXUZXIMQZIMPSQ-ZBRNBAAYSA-N
InChI=1S/C5H12N2O2.C4H7NO4/c6-3-1-2-4(7)5(8)9;5-2(4(8)9)1-3(6)7/h4H,1-3,6-7H2,(H,8,9);2H,1,5H2,(H,6,7)(H,8,9)/t4-;2-/m00/s1
| Molecular Formula | C5H12N2O2 |
| Molecular Weight | 132.161 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H7NO4 |
| Molecular Weight | 133.1027 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00129
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00129
Ornithine is an amino acid produced in the urea cycle by the splitting off of urea from arginine. It is a central part of the urea cycle, which allows for the disposal of excess nitrogen. Ornithine is also a precursor of citrulline and arginine. Arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of arginine in tissues throughout the body. As de novo synthesis of arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to arginine).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) |
112.0 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | L-Ornithine Approved UseUsed for nutritional supplementation, also for treating dietary shortage or imbalance. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of L-arginine on the course of experimental colitis. | 2001-10 |
|
| Allosteric control of the oligomerization of carbamoyl phosphate synthetase from Escherichia coli. | 2001-09-18 |
|
| Interstrand side chain--side chain interactions in a designed beta-hairpin: significance of both lateral and diagonal pairings. | 2001-09-12 |
|
| Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. | 2001-09-11 |
|
| SREA is involved in regulation of siderophore biosynthesis, utilization and uptake in Aspergillus nidulans. | 2001-09 |
|
| Induction of L-arginine transport is inhibited by atrial natriuretic peptide: a peptide hormone as a novel regulator of inducible nitric-oxide synthase substrate availability. | 2001-09 |
|
| Synthesis of six novel N,N-dialkyl derivatives of spermidine and effects on growth of the fungal plant pathogen Pyrenophora avenae. | 2001-08-21 |
|
| Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues. | 2001-08-20 |
|
| Localization of amino acid neurotransmitters following in vitro ischemia and anoxia in the rat retina. | 2001-08-11 |
|
| The Plasmodium falciparum bifunctional ornithine decarboxylase, S-adenosyl-L-methionine decarboxylase, enables a well balanced polyamine synthesis without domain-domain interaction. | 2001-08-10 |
|
| Classical and slow-binding inhibitors of human type II arginase. | 2001-08-07 |
|
| Hyperornithinemia associated with gyrate atrophy of the choroid and retina in a child with myopia. | 2001-08 |
|
| Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. | 2001-08 |
|
| Intrahepatic amino acid and glucose metabolism in a D-galactosamine-induced rat liver failure model. | 2001-08 |
|
| The potential mechanism for glutamine-induced collagen biosynthesis in cultured human skin fibroblasts. | 2001-08 |
|
| Structural requirements for conserved arginine of parathyroid hormone. | 2001-07-31 |
|
| Antifungal activity of three spermidine conjugates. | 2001-07-24 |
|
| Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. | 2001-07-20 |
|
| Abnormal elution behavior of ornitine derivatized with 1-fluoro-2,4-dinitrophenyl-5-leucinamide in advanced Marfey's method. | 2001-07-06 |
|
| Experimental chronic arthritis and granulomatous inflammation induced by bifidobacterium cell walls. | 2001-07-06 |
|
| Metabolic effects of arginine addition to the enteral feeding of critically ill patients. | 2001-07-04 |
|
| Determination of amino acids by ion-exchange chromatography on filter paper spotted blood samples stored at different temperatures and for different periods: comparison with capillary and venous blood. | 2001-07 |
|
| Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. | 2001-07 |
|
| Urea flux in beef steers: effects of forage species and nitrogen fertilization. | 2001-07 |
|
| Medical and surgical therapy of the cystine stone patient. | 2001-07 |
|
| Ornithine aminotransferase messenger RNA expression and enzymatic activity in fetal porcine intestine. | 2001-07 |
|
| Polyamine synthesis and interconversion by the Microsporidian Encephalitozoon cuniculi. | 2001-06-20 |
|
| The remarkable hydrophobic effect of a fatty acid side chain on the microbial growth promoting activity of a synthetic siderophore. | 2001-06 |
|
| Sustained oral lysine supplementation in ornithine delta-aminotransferase deficiency. | 2001-06 |
|
| Detection of neonatal argininosuccinate lyase deficiency by serum tandem mass spectrometry. | 2001-06 |
|
| Methohexital affects neutrophil (PMN) dynamic free amino acid pool and immune functions in vitro. | 2001-06 |
|
| HHH syndrome associated with callosal agenesis and disordered neuronal migration. | 2001-06 |
|
| Involvement of a transformylase enzyme in siderophore synthesis in Pseudomonas aeruginosa. | 2001-06 |
|
| Occupational lead exposure and amino acid profiles and liver function tests in industrial workers. | 2001-06 |
|
| Evidence for a spontaneous nitric oxide release from the rat median eminence: influence on gonadotropin-releasing hormone release. | 2001-06 |
|
| A new receptor molecule for lysine and histidine in water: strong binding of basic amino acid esters by a macrocyclic host. | 2001-05-31 |
|
| Gastrectomized patients are in a state of chronic protein malnutrition analyses of 23 amino acids. | 2001-05-31 |
|
| Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. Part 2. | 2001-05-21 |
|
| Biogenic amines in wines: role of lactic acid bacteria. | 2001-05-15 |
|
| Convenient method for the determination of arginine and its related compounds in rumen fluid by reversed-phase high-performance liquid chromatography. | 2001-05-05 |
|
| Expression, purification, and characterization of human type II arginase. | 2001-05-01 |
|
| [Gyrate atrophy and craniopharyngioma: a case report]. | 2001-05 |
|
| A new technique to elevate night time growth hormone release and a potential growth hormone feedback control loop. | 2001-05 |
|
| Adverse effects of excess lysine in calves. | 2001-05 |
|
| Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection. | 2001-04-13 |
|
| Effect of exercise on the metabolism of vitamin B6 and some PLP-dependent enzymes in young rats fed a restricted vitamin B6 diet. | 2001-04 |
|
| Effects of amino acid and trace element supplementation on pneumocandin production by Glarea lozoyensis: impact on titer, analogue levels, and the identification of new analogues of pneumocandin B(0). | 2001-04 |
|
| Regulation of loblolly pine (Pinus taeda L.) arginase in developing seedling tissue during germination and post-germinative growth. | 2001-03 |
|
| The genome of Mycobacterium leprae: a minimal mycobacterial gene set. | 2001 |
|
| [Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome]. | 2001 |
Patents
Sample Use Guides
Measurement of Ca2+-dependent chloride currents in Xenopus laevis oocytes facilitated the deorphanization of human family C G-protein-coupled receptor hGPRC6A/homologous goldfish 5.24 receptor chimeric construct (h6A/5.24) and identification of L-amino acids as agonists. The most active agonists were L-Arg, L-Lys, and L-ornithine, suggesting that these may function as endogenous signaling molecules (only L-Arg, L-Lys, and L-ornithine were able to activate h6A/5.24 at 10 uM concentration).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:17:50 GMT 2025
by
admin
on
Mon Mar 31 20:17:50 GMT 2025
|
| Record UNII |
JA08T3B97O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
4334 (Number of products:33)
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30883964
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
3230-94-2
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
C002939
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
JA08T3B97O
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
18599
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
32541
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB14714MIG
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
m8239
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
DBSALT002898
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
221-772-7
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
100000080065
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY | |||
|
SUB127311
Created by
admin on Mon Mar 31 20:17:50 GMT 2025 , Edited by admin on Mon Mar 31 20:17:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |